Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Efficacy and safety of first-line orelabrutinib combined with obinutuzumab (With or Without Bendamustine) in high-risk marginal zone lymphoma: Results from the orchid study

View Full Paper
Ask AI
Bookmark
Share

Authors

GWGuolin WuDFDandan FanHSHao Song

Discussion

Loading...

Member takes

Overview

Phase 2 trial shows complete response and high progression-free survival in high-risk marginal zone lymphoma patients, indicating effective treatment.

Key Points

  • This study investigates the efficacy and safety of orelabrutinib combined with obinutuzumab in treating high-risk marginal zone lymphoma.
  • Patients with high-risk marginal zone lymphoma were assigned to Cohort A (without chemotherapy) or Cohort B (with bendamustine) for treatment.
  • Cohort A received orelabrutinib and obinutuzumab, while Cohort B received the same plus bendamustine over 6 cycles.
  • Efficacy endpoints included complete response and overall response rate, with safety assessments for adverse events.
  • Among 20 patients, the treatment achieved a complete response rate of 100% at interim assessment.
  • The estimated 6-month progression-free survival rate was 90%, indicating durability of responses.
  • Adverse events were manageable, with no severe events recorded; mild to moderate toxicities were observed.

Cite This Study

Wu et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da19https://doi.org/10.1182/blood-2025-3597
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Preliminary analysis of orelabrutinib combined with obinutuzumab in the treatment of marginal zone lymphoma (Orion Study)2025
  2. 2Efficacy, safety, and NGS analysis of orelabrutinib combined with obinutuzumab in untreated marginal zone lymphoma2025
  3. 3Orelabrutinib with anti-CD20 monoclonal antibodies is highly effective and well-tolerated as first-line therapy for marginal zone lymphoma2026 · 1 citations
  4. 4Preliminary study results of orelabrutinib in combination with rituximab for treatment-Naïve marginal zone lymphoma: A prospective single-arm clinical trial2025 · 1 citations
  5. 5Orelabrutinib combined with bendamustine-rituximab or obinutuzumab followed by orelabrutinib maintenance in untreated marginal zone lymphoma (Optimize): A multicenter, single-arm, phase II study2025 · 1 citations